Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Mallinckrodt
Colorcon
Dow
Johnson and Johnson

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

PROSTIN VR PEDIATRIC Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Prostin Vr Pediatric patents expire, and when can generic versions of Prostin Vr Pediatric launch?

Prostin Vr Pediatric is a drug marketed by Pharmacia And Upjohn and is included in one NDA.

The generic ingredient in PROSTIN VR PEDIATRIC is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.

US ANDA Litigation and Generic Entry Outlook for Prostin Vr Pediatric

A generic version of PROSTIN VR PEDIATRIC was approved as alprostadil by WEST-WARD PHARMS INT on January 26th, 2020.

  Start Trial

Drug patent expirations by year for PROSTIN VR PEDIATRIC
Drug Prices for PROSTIN VR PEDIATRIC

See drug prices for PROSTIN VR PEDIATRIC

Recent Clinical Trials for PROSTIN VR PEDIATRIC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Department of Obstetrics and Gynaecology, National University HospitalN/A
Yong Loo Lin School of MedicineN/A
National University Hospital, SingaporeN/A

See all PROSTIN VR PEDIATRIC clinical trials

Synonyms for PROSTIN VR PEDIATRIC
(-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate
(-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid
(-)-Protaglandin E1
(+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoate
(+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-Cyclopentaneheptanoic acid
(11?,13E,15S)-11,15-Dihydroxy-9-oxo-prost-13-en-1-oic acid
(11alpha,12alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid
(13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate
(13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic acid
(13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoate
(13E)-(15S)-11,15-dihydroxy-9-oxoprost-13-enoic acid
(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoic acid
(1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
11,15-Dihydroxy-9-oxoprost-13-en-1-oate
11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid
11,15-dihydroxy-9-oxoprost-13-en-1-oic acid (ACD/Name 4.0)
119314-69-1
11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid
22299-37-2
3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate
3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic acid
3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
50-83-9
50865-30-0
7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic acid
7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic acid
7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
7-[(1r,3r)-3-Hydroxy-2-[(1e,3s)-3-Hydroxyoct-1-En-1-Yl]-5-Oxocyclopentyl]heptanoic Acid
7-[(1R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxo-cyclopentyl]heptanoic acid
7-[(1R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
7-[5-((1E)(3S)-3-hydroxyoct-1-enyl)(1R,4R,5R)-4-hydroxy-2-oxocyclopentyl]hepta noic acid
745-65-3
745P653
9-oxo-11R,15S-dihydroxy-13E-prostaenoic acid
AB0014134
AB00514004
AB00514004_09
AB00514004-06
AB00514004-08
AB2000131
AC-6095
AC1L3YXT
AC1NQXHQ
AC1O5FT0
AI3-62116
AKOS015961103
AKOS032960372
Alista
alprostadil
Alprostadil (JP17/USP/INN)
Alprostadil [USAN:INN:BAN:JAN]
Alprostadil [USAN:USP:INN:BAN:JAN]
Alprostadil Prostoglandin E1
Alprostadil, European Pharmacopoeia (EP) Reference Standard
Alprostadil, meets USP testing specifications
Alprostadil, United States Pharmacopeia (USP) Reference Standard
Alprostadil(Caverject)
Alprostadil(usan)
Alprostadilum
Alprostadilum [INN-Latin]
Alprox-TD
API0001428
AS-16360
B2154
BC205461
BCP01740
BCP9000277
BDBM50101853
Befar
Befar (TN)
BG0025
BIDD:GT0747
Bio1_000229
Bio1_000718
Bio1_001207
Bio2_000208
Bio2_000688
BML1-F06
BPBio1_001293
BRD-K48099440-001-01-7
BRD-K52459643-001-06-0
BRD-K52459643-001-10-2
BRD-K52459643-001-17-7
BSPBio_001175
BSPBio_001488
C04741
CAS-745-65-3
Caveject
Caverject
Caverject Impulse
CBiol_001943
CCG-101188
CHEBI:15544
CHEBI:92915
CHEMBL495
CPD000112594
CS-1905
Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)-
Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (+)-
Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, l-
D00180
DB00770
DSSTox_CID_2578
DSSTox_GSID_22578
DSSTox_RID_76640
DTXSID9022578
Edex
EINECS 212-017-2
EX-A1411
F5TD010360
FemLife
Femprox
GMVPRGQOIOIIMI-DODZYUBVSA-N
GMVPRGQOIOIIMI-DWKJAMRDSA-N
GTPL1882
HEI-507
HMS1361K10
HMS1571K17
HMS1791K10
HMS1989K10
HMS2052L11
HMS2090L08
HMS2098K17
HMS3268I09
HMS3402K10
HMS3648O17
HMS3715K17
HY-B0131
IDI1_033958
K274
Kaishi
KBio2_000208
KBio2_002776
KBio2_005344
KBio3_000415
KBio3_000416
KBioGR_000208
KBioSS_000208
l-3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic acid
l-PGE1
l-Prostaglandin E1
Lipo-PGE1
Lipoprost
Liprostin
LMFA03010134
LS-58016
MFCD00077860
Minprog
MLS000758964
MLS001424250
MolPort-003-939-183
MR 256
MR-256
Muse
NC00438
NCGC00016535-01
NCGC00025234-02
NCGC00025234-03
NCGC00025234-04
NCGC00025234-05
NSC 165559
ONO 1608
PDSP2_001567
PGE-1
PGE1
PGE1 Oligomer
PGE1, Prostaglandin E1, powder
PGE1;Prostaglandin E1
PGE1alpha
Prestwick0_001018
Prestwick1_001018
Prestwick2_001018
Prestwick3_001018
Prink
Prink (TN)
Promostan
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13E,15S)-
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer
Prostaglandin E1
Prostaglandin E1, >=98% (HPLC), synthetic
Prostaglandin E1, >=99.0% (TLC)
Prostaglandin E1, 98+%
Prostaglandin E1, powder, gamma-irradiated, BioXtra, suitable for cell culture
Prostaglandin E1, synthetic, powder, BioReagent, suitable for cell culture
Prostaglandin E1; PGE1
Prostaglandin E1;Edex;Muse;Liprostin;Caverject
Prostaglandin E1alpha
Prostaglandin-E1
Prostaglandine E
Prostandin
Prostavasin
Prostin VR
Prostin VR pediatric (TN)
Prostivas
RayVa
RP17688
s1508
SAM001246840
SAM001246845
SAM001247093
SCHEMBL10198573
SCHEMBL2962928
SCHEMBL33317
SMP2_000271
SMR000112594
SPBio_003046
SR-01000597593
SR-01000597593-1
SR-01000597593-5
SR-01000597593-6
SR-01000946253
SR-01000946253-1
ST50826271
Sugiran
SYN3025
Topiglan
Tox21_110482
U 10136
U-10,136
U-10136
UNII-F5TD010360
Vasaprostan
Vazaprostan
Viridal
Vitaros
Vitaros (TN)
W-104416
XPG
ZINC3813088

US Patents and Regulatory Information for PROSTIN VR PEDIATRIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn PROSTIN VR PEDIATRIC alprostadil INJECTABLE;INJECTION 018484-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
AstraZeneca
Dow
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.